To the Editor: How the incidence of adverse events in patients with psoriasis treated with systemic drugs varies over time is not well established. Information on trends in adverse events would be useful in clinical practice to inform the frequency of follow-up visits and laboratory tests. Our objective was to describe the incidence of adverse events over time.
We used a cohort of patients with psoriasis who were receiving systemic therapy, the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) cohort, 1 to calculate the incidence rate of adverse events by period of time. Incidence rate ratios were obtained by using a Poisson mixed-model regression considering the center as a random effect to take within-center clustering of patients into account. Data on 2084 patients and 7282 person-years with 5018 adverse events were included. Detailed baseline characteristics of patients exposed to each drug are described in Table I . Some drugs, such as cyclosporine or infliximab, were associated with higher rates of overall adverse events. For most drugs, rates of overall adverse events were higher in the first year (Table II) . This first-year peak was especially marked for cyclosporine, although it is barely used beyond 1 year. If we focused on serious adverse events (SAEs), rates were much lower than the rates of overall adverse events and higher for cyclosporine and infliximab overall. Rates of abnormal laboratory results showed an increase in the first year in the case of classic drugs, whereas for biologic drugs the incidence stayed constant over time.
We found that overall rates of adverse events were higher during the first year of treatment with all drugs.
One explanation for the pattern of some adverse events being higher in the first year could be explained by information bias, as patients may be more likely to report adverse events in the first year of treatment. 2 Our results are also consistent with those of previous studies reporting adverse events. 3 One hypothesis suggests that patients susceptible to adverse events have their treatment terminated within the first year, resulting in a survivor effect to explain the pattern of adverse effects. 4 After the first year, the remaining population would be less susceptible, and therefore rates of adverse effects would remain constant. Rates of SAEs were constant over time for all drugs, and it seems likely that most SAEs were not detected by planned visits but were the cause of an unplanned demand for care. 5 Our findings provide evidence for planning follow-up visits that should be more intensive in the first year for all drugs. This is more relevant for patients receiving classic systemic drugs, when well-known side effects are more likely to appear. Some drugs, such as cyclosporine or infliximab, might require more intensive follow-up. After this first year, less intense and evenly spaced reviews and testing seem appropriate (indefinitely or at least for the first 3 years of treatment according to our data). Rates of SAEs are also constant over time for all drugs, so the effort to detect them should be constant, although they might not be detected by routine visits but instead lead to unexpected consultations. 
